|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date15 Nov 2022 |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase II Study to Assess the Safety and Efficacy of PTS100 in Primary Hepatocellular Carcinoma Patients Who Are Ineligible for Operation or Current Locoregional Therapy
This study is being performed to evaluate the efficacy and safety of 30% PTS100 of total tumor volume as intra-tumoral injection therapy in primary Hepatocellular Carcinoma patients who are ineligible for operation or local regional therapy.
100 Clinical Results associated with Gongwin Biopharm Holdings Co., Ltd.
0 Patents (Medical) associated with Gongwin Biopharm Holdings Co., Ltd.
100 Deals associated with Gongwin Biopharm Holdings Co., Ltd.
100 Translational Medicine associated with Gongwin Biopharm Holdings Co., Ltd.